Filing Details

Accession Number:
0001493152-21-028917
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-16 15:09:58
Reporting Period:
2021-10-18
Accepted Time:
2021-11-16 15:09:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1833214 Sab Biotherapeutics Inc. SABS Biological Products, (No Disgnostic Substances) (2836) 853899721
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1889754 P Russell Beyer 2100 E 54Th Street North
Sioux Falls SD 57104
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-10-18 2,475 $10.10 2,475 No 4 A Direct
Common Stock Acquisiton 2021-09-28 149 $10.08 149 No 4 A Indirect By spouse
Common Stock Acquisiton 2021-10-25 129 $7.78 278 No 4 A Indirect By spouse
Common Stock Disposition 2021-10-26 278 $7.90 0 No 4 S Indirect By spouse
Common Stock Acquisiton 2021-09-28 5 $10.07 5 No 4 A Indirect By daughter
Common Stock Acquisiton 2021-09-29 10 $10.08 15 No 4 A Indirect By daughter
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Indirect By spouse
No 4 A Indirect By spouse
No 4 S Indirect By spouse
No 4 A Indirect By daughter
No 4 A Indirect By daughter
Footnotes
  1. This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.
  2. The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction.